Spots Global Cancer Trial Database for bcnu
Every month we try and update this database with for bcnu cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma | NCT00499018 | Diffuse Large B... IPI≥2 | Rituximab Ciclofosfamide Doxorubicina Vincristina Prednisone Pegfilgrastim Mitoxantrone ARA-C Lenograstim BCNU ARA-C VP-16 ASCT Ciclofosfamide Doxorubicina Vincristina | 18 Years - 60 Years | Fondazione Italiana Linfomi - ETS | |
| Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies | NCT00477035 | Leukemia Multiple Myelom... | CIK cells etoposide bcnu cyclophosphamid... gemcitabine vinorelbine melphalan | 18 Years - 75 Years | Stanford University | |
| Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT | NCT00350181 | Leukemia Lymphoma, Non-H... Hematologic Dis... Acute GVHD | Sirolimus MMF BCNU VP-16 CY FTBI BU | 2 Years - 60 Years | Stanford University | |
| Autologous Transplant in HIV Patients (BMT CTN 0803) | NCT01141712 | Lymphoma HIV | Autologous tran... BCNU Etoposide Cytarabine Melphalan | 15 Years - | Medical College of Wisconsin | |
| CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | NCT00968760 | Lymphoma B-cell Lymphoma | Leukapheresis Stem Cell Trans... CD19-specific T... IL-2 Carmustine Etoposide Cytarabine Melphalan | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies | NCT00472056 | Lymphoma | Carmustine Etoposide Cytarabine Melphalan Rituximab | - 80 Years | M.D. Anderson Cancer Center | |
| Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma | NCT00505921 | Lymphoma | Campath-1H G-CSF GM-CSF BCNU Stem Cell Trans... Preparative Reg... Cytarabine Etoposide Melphalan Campath Fludarabine Cyclophosphamid... Low dose total ... | - 70 Years | M.D. Anderson Cancer Center | |
| Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation | NCT00591630 | Diffuse Large C... Lymphoma | Zevalin Carmustine Etoposide Cytarabine Melphalan Rituximab Stem Cell Trans... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | NCT00005613 | Lymphoma | cyclophosphamid... etoposide BCNU | 15 Years - 55 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease | NCT01702961 | Lymphoma Hodgkin's Disea... | Melphalan Ara-C VP-16 BCNU Rituxan Stem Cells | - | Baylor College of Medicine | |
| Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis | NCT03591861 | Pediatric Brain... | Ketogenic diet BCNU | - 21 Years | Washington University School of Medicine | |
| Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | NCT01538472 | Lymphoma | Y Zevalin In Zevalin Rituxan BCNU VP -16 Ara-C Melphalan Stem Cell Infus... G-CSF | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | NCT01538472 | Lymphoma | Y Zevalin In Zevalin Rituxan BCNU VP -16 Ara-C Melphalan Stem Cell Infus... G-CSF | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT | NCT00350181 | Leukemia Lymphoma, Non-H... Hematologic Dis... Acute GVHD | Sirolimus MMF BCNU VP-16 CY FTBI BU | 2 Years - 60 Years | Stanford University | |
| Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease | NCT01702961 | Lymphoma Hodgkin's Disea... | Melphalan Ara-C VP-16 BCNU Rituxan Stem Cells | - | Baylor College of Medicine | |
| Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma | NCT01011920 | Central Nervous... | Methotrexate Ara-C Rituximab Thiotepa radiotherapy BCNU APBSCT | 18 Years - 65 Years | International Extranodal Lymphoma Study Group (IELSG) | |
| Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | NCT00005613 | Lymphoma | cyclophosphamid... etoposide BCNU | 15 Years - 55 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy | NCT00083551 | Multiple Myelom... | Thalidomide Ara-C BCNU Cisplatin Cytoxan Dexamethasone Doxorubicin Etoposide Filgrastim Recombinant GM-... Interferon-alph... Melphalan Vincristine | 18 Years - 75 Years | University of Arkansas | |
| Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme. | NCT00645385 | Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... | MRS Spectroscop... | 18 Years - 85 Years | Weill Medical College of Cornell University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
